

Allelic strengths of encephalopathy-associated *UBA5* variants correlate between *in vivo* and *in vitro* assays

Xueyang Pan^{1,2}, Albert N. Alvarez³, Mengqi Ma^{1,2}, Shenzhao Lu^{1,2}, Michael W. Crawford³, Lauren C. Briere⁴, Oguz Kanca^{1,2}, Shinya Yamamoto^{1,2,5}, David A. Sweetser^{4,6}, Jenny L. Wilson⁷, Ruth J. Napier^{3,8,9}, Jonathan N. Pruneda^{3,#}, Hugo J. Bellen^{1,2,5,#}

1 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA

2 Jan & Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA

3 Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA

4 Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

5 Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA

6 Division of Medical Genetics & Metabolism, Massachusetts General Hospital for Children, Boston, MA 02114, USA

7 Division of Pediatric Neurology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA

8 VA Portland Health Care System, Portland, OR 97239, USA

9 Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR 97239, USA

Correspondence: hbellen@bcm.edu, pruneda@ohsu.edu

Abstract

Protein UFMylation downstream of the E1 enzyme UBA5 plays essential roles in development and ER stress. Variants in the *UBA5* gene are associated with developmental and epileptic encephalopathy 44 (DEE44), an autosomal recessive disorder characterized by early-onset encephalopathy, movement abnormalities, global developmental delay, intellectual disability, and seizures. DEE44 is caused by at least twelve different missense variants described as loss of function (LoF), but the relationships between genotypes and molecular or clinical phenotypes remains to be established. We developed a humanized *UBA5* fly model and biochemical activity assays in order to describe *in vivo* and *in vitro* genotype-phenotype relationships across the *UBA5* allelic series. *In vivo*, we observed a broad spectrum of phenotypes in viability, developmental timing, lifespan, locomotor activity, and bang sensitivity. A range of functional effects was also observed *in vitro* across comprehensive biochemical assays for protein stability, ATP binding, UFM1 activation, and UFM1 transthiolation. Importantly, there is a strong correlation between *in vivo* and *in vitro* phenotypes, establishing a classification of LoF variants into mild, intermediate, and severe allelic strengths. By systemically evaluating *UBA5* variants across *in vivo* and *in vitro* platforms, this study provides a foundation for more basic and translational UBA5 research, as well as a basis for evaluating current and future individuals afflicted with this rare disease.

1 Introduction

2 Variants in the human *ubiquitin like modifier activating enzyme 5 (UBA5)* gene have been associated
3 with three autosomal recessive disorders. In most reported cases, biallelic *UBA5* variants cause
4 developmental and epileptic encephalopathy 44 (DEE44, OMIM: #617132). The disease is
5 characterized by early-onset encephalopathy, movement abnormalities, global developmental delay,
6 and intellectual disability. Many individuals also have seizures, failure to thrive, and microcephaly.
7 Delayed myelination, thinning of the corpus callosum, and white matter hyperintensities have also
8 been documented with magnetic resonance imaging (MRI) (Colin *et al*, 2016; Muona *et al*, 2016).
9 Biallelic *UBA5* has also been associated with spinocerebellar ataxia 24 (OMIM: #617133), which is
10 characterized by a childhood-onset gait and limb ataxia (Duan *et al*, 2016). Another family has been
11 reported with a rare homozygous missense variant in *UBA5* that segregates with severe congenital
12 neuropathy (Cabrera-Serrano *et al*, 2020).

13 *UBA5* is a key component in UFMylation, a post-translational modification pathway mediated by a
14 ubiquitin-like protein (UBL) ubiquitin fold modifier 1 (UFM1) (Millrine *et al*, 2023). UBL modifications
15 play an essential role in eukaryotic biology by regulating protein stability and function via different
16 enzymatic complexes (Cappadocia & Lima, 2018; van der Veen & Ploegh, 2012). UFMylation is
17 conserved in metazoans and plants (Figure 1A) (Millrine *et al*, 2023). In this pathway, UFM1 is first
18 proteolytically processed by a UFM1 specific peptidase 1/2 (UFSP1/2) to expose a C-terminal Gly
19 (Kang *et al*, 2007; Komatsu *et al*, 2004; Millrine *et al*, 2022). The ensuing conjugation process
20 involves three steps. The first two steps are facilitated by *UBA5*, an E1 activating enzyme specific
21 to UFMylation. *UBA5* activates UFM1 through ATP-dependent adenylation of the UFM1 C-terminal
22 Gly, which is then transferred onto the *UBA5* active site Cys 250, forming a high-energy thioester
23 intermediate. Next, the UFM1-specific E2 conjugating enzyme, UFC1, binds to the activated
24 *UBA5*~UFM1 intermediate and receives UFM1 onto its active site Cys through a transthioation
25 reaction (Figure 1A) (Gavin *et al*, 2014; Komatsu *et al*, 2004). The UFM1 activation and
26 transthioation processes are achieved by a trans-binding mechanism involving two molecules each
27 of *UBA5*, UFM1, and UFC1, wherein one *UBA5* protomer performs the enzymatic processes while
28 the other provides essential UFM1- and UFC1-binding sites *in trans* (Figure 1B) (Kumar *et al*, 2021;
29 Mashahreh *et al*, 2018; Oweis *et al*, 2016). Next, the E3 ligase UFL1 functions as a scaffold to bring
30 the activated UFC1~UFM1 conjugate to the substrate protein and facilitate the conjugation of UFM1
31 to a substrate Lys residue (Peter *et al*, 2022; Tatsumi *et al*, 2010).

32 UFMylation has been implicated in regulating many processes such as genome stability and
33 receptor activation (Liu *et al*, 2020; Qin *et al*, 2019; Wang *et al*, 2019; Yoo *et al*, 2014), but the
34 principal role is believed to be in regulating proteotoxic stress at the endoplasmic reticulum (ER),
35 where UFMylation of stalled ribosomes initiates quality control measures (Liang *et al*, 2020; Scavone
36 *et al*, 2023; Walczak *et al*, 2019; Wang *et al*, 2020). So far, the only well-characterized *Uba5* mutant
37 animal model is a mouse model in which removal of the gene causes embryonic lethality due to
38 hematopoietic defects (Tatsumi *et al*, 2011). Tissue-specific mouse knockouts of other genes within
39 the UFMylation pathway support a role in regulating ER stress within secretory cells, as well as a
40 critical developmental role within the central nervous system (Muona *et al*, 2016; Zhu *et al*, 2019).

41 To date, 24 individuals from 17 families who have *UBA5*-associated DEE44 have been reported
42 (Arnadottir *et al*, 2017; Briere *et al*, 2021; Colin *et al*, 2016; Daida *et al*, 2018; Low *et al*, 2019;
43 Mignon-Ravix *et al*, 2018; Muona *et al*, 2016). The genotypes (Table S1) and clinical features (Table
44 S2) of the affected individuals are summarized in Supplemental Information. Prior functional studies
45 using cultured cells or patient cells show that many reported *UBA5* variants cause various levels of
46 loss of function (LoF). However, the study of the genotype-phenotype relationship is hampered by
47 the limited number of affected individuals, incomplete description of clinical presentations and the
48 heterogeneous genetic background. Variant-specific *in vivo* models are powerful tools for studying
49 genotype-phenotype relationship, especially for rare diseases (Arnadottir *et al*, 2017; Goodman *et al*,
50 2021; Lu *et al*, 2022a; Lu *et al*, 2022b; Ma *et al*, 2023; Tepe *et al*, 2023). However, systematic
51 assessment of the effects of disease-causing variants *in vivo* is a challenge as it can be very labor

1 intensive. Moreover, the *in vivo* assays should be compared to functional studies of the variant
2 proteins, which typically relies on biochemical or other cell-based assays that are not available for
3 most proteins/genes. By combining phenotypic studies and biochemical assays it should be possible
4 to assess the severity of each variant, providing valuable information for the affected individuals and
5 for assessing possible therapeutic interventions. In addition, genotype-phenotype relationships offer
6 information about the molecular basis underlying variants LoF, paving the way for future therapeutic
7 development.

8 In this study, we assess the genotype-phenotype relationship in *UBA5*-associated DEE44 variants
9 by determining the phenotypes of variant-specific fruit fly models. In conjunction with the *in vivo* data,
10 we also comprehensively assess the biochemical properties of each variant using assays that report
11 on protein stability, ATP binding, UFM1 activation, and UFM1 transthiolation. The presence and
12 severity of the phenotypes in flies are highly variant-dependent. Similarly, the enzymatic activities of
13 the variants vary widely *in vitro*. Interestingly, both *in vivo* and *in vitro* assays produce a very similar
14 allelic series for the variants, suggesting a correlation between specific enzymatic properties and
15 the phenotypes in the animal models. Finally, combining our animal model work with available
16 insights into *UBA5* enzymology provides us with a much better understanding of the structure-
17 function relationship of the *UBA5* variants.

18 19 **Results**

20 *Establishment of a variant-specific UBA5-associated disease model in fruit flies*

21 To investigate the functions of *UBA5* variants *in vivo*, we utilized *Drosophila melanogaster* as a
22 model organism. *Uba5* is the ortholog of human *UBA5* in flies (*UBA5* refers to the human gene;
23 *Uba5* refers to the fly gene). The two proteins share 64% identity and 75% similarity in amino acid
24 sequence, and the *Drosophila* Integrative Ortholog Prediction Tool (DIOPT) score between *UBA5*
25 and *Uba5* is 15/16, indicating a high degree of homology (Figure 1C) (Hu *et al.*, 2021). The *UBA5*
26 protein has an adenylation domain, a UFM1-interacting sequence (UIS) and a UFC1-binding
27 sequence (UBS), all of which are required for UFM1 activation and transthiolation (Bacik *et al.*, 2010;
28 Habisov *et al.*, 2016; Kumar *et al.*, 2021; Padala *et al.*, 2017; Xie, 2014) (Figure 1C). Similarly, *Uba5*
29 has all three highly conserved functional domains, and all of the amino acid residues affected by the
30 DEE44-associated variants reported so far are conserved in the fly protein (Figure 1C).

31 To study the variant-specific functions, we generated humanized fruit fly models in which the
32 expression of the endogenous *Uba5* gene is removed or severely suppressed and a human *UBA5*
33 cDNA is expressed under the control of the endogenous *Uba5* enhancer and promoter. If the human
34 reference *UBA5* functions in flies and rescues the *Uba5* severe LoF phenotypes, the DEE44-
35 associated variants can be expressed and their functions can be assessed by the phenotypes of
36 flies. To achieve this, we generated a *Uba5^{T2A-Gal4}* allele using a CRISPR-Mediated Integration
37 Cassette (CRIMIC) strategy (Lee *et al.*, 2018). In the *Uba5^{T2A-Gal4}* allele, an *FRT-Splice Acceptor*
38 (*SA*)-*T2A-GAL4-polyA-FRT* cassette was inserted into a coding intron of the *Uba5* gene. The SA
39 causes the inclusion of the cassette during transcription, while the polyA sequence arrests the
40 transcription generating a truncated transcript. The translation of the transcript is arrested at the viral
41 ribosomal skipping site (T2A) and reinitiated after the site, producing an untagged GAL4 protein
42 (Figure 1D) (Diao *et al.*, 2015; Lee *et al.*, 2018). The *Uba5^{T2A-Gal4}* allele is likely a severe LoF allele
43 (see below) (Lee *et al.*, 2018). In addition, this allele also results in the expression of GAL4 under
44 the control of the endogenous *Uba5* enhancer and promoter, which enables the assessment of
45 native gene expression pattern as well as the expression of human *UBA5* cDNA (Figure 1D). We
46 also generated a *Uba5* null allele by CRISPR-induced indel formation (*Uba5^{p.Arg55Profs*87}*, named
47 *Uba5^{KO}*) (Figure 1E).

48 We first tested the viability of the flies with the *Uba5^{T2A-Gal4}* and the *Uba5^{KO}* alleles. The fly *Uba5*
49 gene is located on the X chromosome. For both alleles, homozygous female and hemizygous male

1 flies are lethal at the embryonic stage, although a few *Uba5*^{T2A-Gal4} escapers survive to the L1 larval
2 stage (Figure 1F). The lethality is rescued by a genomic rescue (GR) construct that carries the *Uba5*
3 locus (P[acman] clone CH321-02B13) (Venken *et al*, 2010), indicating that the lethality in both lines
4 is caused by the LoF of *Uba5*. Moreover, expression of flippase (FLP) using *Uba5*^{T2A-Gal4} removes
5 the insertion of the CRIMIC cassette and reverts the lethality of the *Uba5*^{T2A-Gal4} hemizygous males,
6 showing that the lethality is indeed caused by the *Uba5*^{T2A-Gal4} allele (Figure 1F) (Lee *et al.*, 2018).
7 Finally, expression of reference human *UBA5* cDNA using *Uba5*^{T2A-Gal4} rescues the lethality of the
8 mutants, showing that the functions of the fly and human proteins are evolutionarily conserved
9 (Figure 1F).

11 *Uba5* is expressed in a subset of neurons and glia in the fly central nervous system

12 Next, we examined the expression pattern of *Uba5* by expressing a nuclear localized mCherry
13 fluorescent protein (*UAS-mCherry.nls*) under the control of *Uba5*^{T2A-Gal4}. *Uba5* is expressed in
14 multiple tissues in L3 larvae and adult flies (Figure 2A), consistent with high-throughput gene
15 expression profiling results (Fig. S2A) (Leader *et al*, 2018; Li *et al*, 2022). We next analyzed the
16 expression of *Uba5* in the central nervous system (CNS). We stained the *Uba5*^{T2A-Gal4}>*mCherry.nls*
17 larval CNS and adult brain with anti-Elav and anti-Repo antibodies to mark the nuclei of neurons
18 and glial cells, respectively. In both larval CNS and adult brain, the mCherry.nls signals are found in
19 a subset of neurons and glia (Figures 2B and 2C), suggesting that *Uba5* is expressed in the fly CNS
20 but not in all cells. This finding is also consistent with the previously published single-cell RNA
21 sequencing profile (Fig. S2B) (Davie *et al*, 2018). *Uba5* is expressed more widely in the adult brains
22 than in the larval CNS. In larval CNS, it is expressed in many fewer neurons than Elav (Figures 2A
23 and 2B). The expression pattern resembles that of the *para* gene, which encodes the sole voltage-
24 gated sodium channel in *Drosophila* that is only expressed in differentiated, actively firing neurons
25 (Ravenscroft *et al*, 2020). This suggests that UBA5 may be required for the activity of neurons.

26 Since *Uba5* is expressed in multiple tissues in flies, we sought to determine the tissue specific
27 requirement of *Uba5* for fly development. We expressed the reference *UBA5* cDNA in *Uba5*^{KO}
28 hemizygous mutants using various GAL4 drivers and examined the viability of the animals.
29 Ubiquitous expression of *UBA5* by *da-Gal4* or *Act-Gal4* fully rescues the lethality of the mutant
30 animals. However, tissue-specific expression of *UBA5* in fat body (*lpp-Gal4*), muscles (*Mef2-Gal4*),
31 neurons (*Elav-Gal4*), or glial cells (*Repo-Gal4*) fails to rescue the lethality (Fig. S2C). Hence, we
32 conclude that *Uba5* is required in multiple tissues. Interestingly, overexpression of *UBA5* in *Uba5*^{KO/+}
33 heterozygous flies does not cause any obvious phenotype (Fig. S2C), showing that *Uba5*
34 overexpression is not overtly toxic.

36 *DEE44-associated variants exhibit different rescuing abilities in flies*

37 Next, we sought to evaluate the function of *UBA5* variants using the humanized fly model (Bellen &
38 Yamamoto, 2015). We expressed reference or variant *UBA5* cDNA and DEE44-associated *UBA5*
39 variants using *Uba5*^{T2A-Gal4} and measured phenotypes including survival rate, developmental timing,
40 lifespan, locomotor activity, and seizure-like activity following mechanical stimulation in *Uba5*^{T2A-Gal4}
41 hemizygous male flies. The variants we tested include all previously reported variants (Arnadottir *et al.*
42 *et al.*, 2017; Briere *et al.*, 2021; Colin *et al.*, 2016; Daida *et al.*, 2018; Low *et al.*, 2019; Mignon-Ravix
43 *et al.*, 2018; Muona *et al.*, 2016), as well as a novel variant from an individual we report in this study.
44 This individual has compound heterozygous variants in *UBA5*, p.Met57Val and p.Gln312Leu (Table
45 S3), and presents with hypotonia, generalized dystonia, lower extremity spasticity, global
46 developmental delay, and failure to thrive. However, this individual is so far seizure free. Further
47 clinical details of the individual are summarized in Supplemental Information.

48 We first assessed the ability of the variants to rescue the lethality of *Uba5*^{T2A-Gal4} mutants. Flies were
49 raised at three different temperatures: 29 °C, 25 °C, and 18 °C. Lower temperatures lead to lower

1 expression levels of *UBA5* when compared to higher temperatures (Nagarkar-Jaiswal *et al*, 2015).
2 At all temperatures, a synthetic enzyme-dead *UBA5* mutant p.Cys250Ala failed to rescue lethality
3 (Figure 3A). Similarly, four DEE44-associated variants (p.Arg55His, p.Gly168Glu, p.Leu254Pro,
4 p.Cys303Arg) failed to rescue the lethality at all temperatures tested, indicating that they are severe
5 LoF. Three variants (p.Tyr53Phe, p.Met57Val, p.Val260Met) partially rescued the lethality at 18 °C
6 and the survival rate increased at elevated temperatures (Figure 3A). This suggests that the three
7 variants are likely hypomorphic alleles and supports a dosage-sensitive effect of *Uba5*. However,
8 six variants (p.Arg72Cys, p.Val260Met, p.Gln312Leu, p.Ala371Thr, p.Asp389Gly, p.Asp389Tyr) fully
9 rescued lethality, suggesting they are mild LoF or do not affect protein function. Based on these
10 results, we stratified the variants into three groups according to the activity of rescuing lethality:
11 Group I, full rescue; Group II, partial rescue; Group III, failure to rescue (Table 1, Group I was further
12 divided into IA and IB according to the other phenotypes described below).

13 The variants that survive to adults were next tested for the time it takes for animals to eclose as
14 adults, and lifespan. The variants in Group II exhibited significant developmental delay as well as a
15 shortened lifespan, showing that they are partial LoF (Figures 3B and 3C). In contrast, some variants
16 in Group I (Group 1A: p.Ala371Thr, p.Asp389Gly, and p.Asp389Tyr) caused neither defect. Other
17 Group I variants (Group 1B: p.Arg72Cys and p.Gln312Leu) caused a shortened lifespan but did not
18 affect the timing of development (Figures 3B and 3C), indicating that they are also partial LoF
19 variants but could cause milder defects than Group II variants.

20 To determine if the flies display features that are associated with dysfunction of the nervous system,
21 we measured locomotor activity using a climbing assay and assessed susceptibility to seizures
22 using a bang sensitivity assay (Song & Tanouye, 2008). Flies with variants in Groups IB and II
23 displayed reduced climbing activity at Day 7 and more severe defects by Day 30, showing a
24 progressive worsening of the defects (Figure 3D). Moreover, the variants in Group II exhibited a
25 bang-sensitive phenotype by displaying seizure-like behavior and paralysis following mechanical
26 stimulation (Figure 3E). However, the Group IA variants displayed neither a climbing defect nor bang
27 sensitivity (Figures 3D and 3E). These results are consistent with our classification of variants based
28 on other assays: Group IA, no obvious LoF or benign; Groups IB and II, intermediate LoF; and Group
29 III, severe LoF.

30 Given the observed neurological defects, we tested whether the variants affect the synapse
31 morphology of the neuromuscular junctions (NMJs) in third instar larvae. Although a previous study
32 reported that knockdown of *Uba5* in motor neurons caused decreased number and increased size
33 of synaptic boutons at the NMJs (Duan *et al.*, 2016), we did not observe any obvious changes in
34 bouton number or size caused by the Group II variants (Figure S3A-S3C). Hence, we conclude that
35 the synaptic growth of fly larvae is not affected by the *UBA5* variants.

36 37 *Structural analysis of UBA5 variants*

38 In order to link our findings in the fly model with functional changes in *UBA5*, we first analyzed the
39 potential structural changes caused by the *UBA5* variants. Extensive structural analyses have been
40 performed on *UBA5*, including its ability to bind ATP and homodimerize within the adenylation
41 domain, its interaction with UFM1 in the process of activation, and its engagement of UFC1 prior to
42 UFM1 transthiolation (Bacik *et al.*, 2010; Kumar *et al.*, 2021; Oweis *et al.*, 2016; Padala *et al.*, 2017;
43 Soudah *et al.*, 2019; Wesch *et al.*, 2021). This structural detail of *UBA5* function offers a unique
44 opportunity to visualize the location of variants and categorize their predicted effects. We compiled
45 a series of *UBA5* structures to create a composite model that illustrates a) *UBA5* homodimerization,
46 b) ATP coordination, c) UFM1 binding, and d) UFC1 binding (Figure 4A). Focusing on the UFM1 C-
47 terminal Gly and the active site Cys residues of *UBA5* and UFC1, the movements that occur during
48 UFM1 activation and transthiolation can be mapped (Figure 4A, yellow spheres).

49 With this structural model as a basis, we highlighted the location of all *UBA5* variants (Figure 4A,

red spheres). Variants at positions Asp389 and Ala371 lie outside of the regions with determined structure, so their locations are modeled based on all available data. All Group IA variants localize in proximity of the UBS in protein sequence. The p.Asp389Gly and p.Asp389Tyr variants affect Asp389 which is two amino acids upstream of the structurally-resolved UBS. For p.Ala371Thr, although there is no structure of this region, previous biochemical and crosslinking data have demonstrated its proximity to the UFC1 active site (Kumar *et al.*, 2021). Four variants, p.Tyr53Phe, p.Arg55His, p.Met57Val, and p.Arg72Cys, affect residues near the ATP-binding site (Figure 4B). The side chain of Arg55 makes direct contacts to the bound ATP, while Met57 and Tyr53 make secondary contacts behind this site, and Arg72 makes more distant tertiary contacts. Substitutions at these positions, therefore, may affect the affinity of UBA5 toward ATP. Residue Leu254 is four amino acids downstream of the active site Cys250, contained within a loop region that must undergo conformational changes to support UFM1 activation and subsequent transthiolation (Figures 4A and 4B). The Pro substitution within the p.Leu254Pro variant may constrain the required flexibility of the Cys250 loop, thus impacting ATP binding, UFM1 activation, and UFM1 transthiolation. Val260 is buried within the UBA5 homodimeric interface, opposing residue Val260 of the second protomer (Figure 4B). The increased size of the p.Val260Met variant may cause a steric clash that reduces UBA5 dimerization, which would decrease ATP binding, UFM1 activation, and UFM1 transthiolation as a result. Positions Cys303 and Gly168 are fully buried, making structural contacts to support the fold of the adenylation domain (Figure 4C). The increased size and charge associated with the p.Cys303Arg and p.Gly168Glu variants would most likely cause significant defects in UBA5 folding and stability. Lastly, the site of the novel p.Gln312Leu variant reported here is partially buried, making structural contacts to a loop region underneath the UFM1-binding site, and thus substitutions at this site may also cause structural instability (Figure 4C).

Generation and characterization of purified UBA5 variant proteins

To determine the functional capacity of the UBA5 variants, we expressed and purified reference and variant UBA5 proteins from *Escherichia coli* for biochemical assays. Two severe LoF (Group III) variants p.Gly168Glu and p.Cys303Arg were insoluble in the protein purification process, indicating that the variants influence the stability and/or folding of these proteins. We were able to obtain pure and homogeneous samples of all other UBA5 constructs (Figure 5A). For our first measure of UBA5 function, we measured the effects of each variant on protein stability using a thermal shift assay. Under our assay conditions, reference UBA5 demonstrated a melting temperature (T_m) of 46 °C. While most UBA5 variants exhibited little-to-no change in T_m , several showed a subtle destabilization by ≥ 1 °C, including p.Arg72Cys, p.Leu254Pro, p.Val260Met, and p.Ala371Thr (Figure 5B). Interestingly, the Group IB variant p.Gln312Leu exhibited a minor unfolding at 36 °C before fully melting at 48 °C. This could indicate destabilization in the local structure surrounding the Gln312Leu substitution, while leaving the remaining protein structure intact.

Ligand binding can stabilize protein structure and lead to a shift in T_m toward higher temperatures. This has been shown previously in the case of UBA5 binding to ATP, where it was determined to interact with a K_D of ~ 700 μ M (Mashahreh *et al.*, 2018). The ATP-dependent stabilization of UBA5 allowed us to assess mutational effects on ATP binding using the thermal shift assay. Whereas addition of 5 mM ATP led to a strong, 13 °C shift in the T_m of reference UBA5, many of the variants exhibited much weaker stabilization, indicative of a diminished capacity to bind ATP (Figure 5C). The other two Group III variants and one Group II variant p.Tyr53Phe showed the strongest defect, with only 4-5 °C shifts in T_m upon addition of ATP. The Group II variants p.Met57Val and p.Val260Met as well as one Group IB variant p.Gln312Leu showed a milder effect with a 6-8 °C shift in T_m . One Group IB variant p.Arg72Cys and all Group IA variants showed similar ATP-dependent stabilization to reference UBA5. Unlike the melting trend observed in the absence of ATP, in the presence of ATP the p.Gln312Leu variant displayed a single unfolding profile, suggesting that ATP binding corrected the local instability caused by the substitution.

1 These results show that not all tested variants strongly affect the stability of UBA5 protein. However,
2 many variants impair the ATP binding capability of the protein. The levels of impairment correlate
3 well with the phenotypic observations *in vivo* (Table 1 and 2), suggesting that the defect in ATP
4 binding is a major contributor to the LoF associated with the variants. Consistent with their severe
5 LoF *in vivo*, variants p.Gly168Glu and p.Cys303Arg exhibited impaired protein folding and could not
6 be included in our *in vitro* analyses.

8 *Visualizing mutational effects on UFM1 activation and transthiolation*

9 Previous functional characterization of UBA5 activity has relied upon gel-based assays that often
10 lack kinetic information and are less sensitive to subtle changes. We sought to address this problem
11 by developing a real-time, fluorescence polarization (FP) assay for UBA5 activity based upon a
12 method we coined “UbiReal” (Franklin & Pruneda, 2019, 2023). The approach leverages the large
13 changes in molecular weight that occur as UFM1 is activated by UBA5 and transferred to UFC1
14 (Figure 6A), which are read out as changes in FP of fluorescently-labeled UFM1. Indeed, upon
15 addition of UBA5 we observed a large shift in FP of Alexa488-labeled UFM1, which reached a
16 plateau over the course of ~20 minutes under these conditions (Figure 6B). Addition of UFC1 to the
17 reaction caused a concomitant downward shift in FP that reached a new plateau within ~5 minutes.
18 To validate the molecular species observed in this assay, we ran samples from each stage of the
19 reaction on non-reducing SDS-PAGE and were able to visualize free UFM1, UBA5~UFM1, and
20 UFC1~UFM1 as predicted (Figure 6C).

21 With the UFM1 UbiReal assay in hand, we proceeded to assess the effects of UBA5 variant on the
22 first step of the reaction: UFM1 activation. As anticipated, addition of reference UBA5 caused a rapid
23 shift in FP over time, whereas the enzyme-dead p.Cys250Ala variant remained at baseline (Figure
24 6D). We quantified these kinetic data with Area Under the Curve (AUC) analysis using data collected
25 just before addition of UBA5 to establish a baseline. The panel of UBA5 variants displayed a wide
26 range of effects. The two Group III variants p.Arg55His and p.Leu254Pro remained near the baseline,
27 indicating a severe impairment in UFM1-activating function. An intermediate, statistically significant
28 effect was observed with the p.Val260Met variant (Group II), while the remaining variants showed
29 mild or, in the case of p.Ala371Thr (Group IA), no decrease in the rate of UFM1 activation (Figure
30 6E). Similar trends were observed at both 22 °C and 37 °C, though interestingly the effect of
31 p.Val260Met substitution was less severe at higher temperature (Figure 6F). The results show that
32 a defect in UFM1 activation contributes to the LoF in all variants except for p.Ala371Thr. The severity
33 of LoF in UFM1 activation correlates with our phenotypic observations *in vivo* (Table 1 and 2).

34 Having observed defects in UFM1 activation for many of the UBA5 variants, we next analyzed those
35 that exhibited mild or no effect for their ability to complete the second enzymatic role of UBA5: UFM1
36 transthiolation onto UFC1. After forming the activated UBA5~UFM1 intermediates, we added UFC1
37 to the reactions and monitored the decay in FP over time (Figure 6G). Though many of the UBA5
38 variants showed similar trends for transthiolation, the p.Ala371Thr variant immediately stood out for
39 having no effect on UFM1 activation (Figures 6D-6F), but a greatly impaired ability to transfer UFM1
40 onto UFC1 (Figure 6G). We quantified the kinetic data using AUC analysis of the inverted curve and
41 observed a remarkable defect in the ability of the p.Ala371Thr variant to catalyze UFM1
42 transthiolation (Figure 6H). Interestingly, this defect is much more pronounced at 22 °C than at 37
43 °C (Figure 6I). These results suggest that aside from a minor decrease in UBA5 stability (Figure 5B),
44 UFM1 transthiolation is the only possible defect caused by the p.Ala371Thr variant. Transthiolation
45 could be defective in other variants as well, such as p.Leu254Pro (Group III), but this effect is likely
46 overshadowed by upstream effects on UBA5 stability, ATP binding, and/or UFM1 activation.

48 **Discussion**

49 In this study, we assessed the strength and properties of variants identified in individuals with DEE44

1 using a humanization strategy in fruit flies. Germline knockout of *Uba5* causes embryonic lethality
2 in both flies (this study) and mice (Tatsumi *et al.*, 2011), and no individuals have been identified with
3 biallelic null variants in humans. The lethality of *Uba5* knockout mice is caused by hematopoietic
4 defects (Tatsumi *et al.*, 2011), however, the clinical presentations in DEE44 patients are
5 predominantly related to the central nervous system (Arnadottir *et al.*, 2017; Briere *et al.*, 2021; Colin
6 *et al.*, 2016; Daida *et al.*, 2018; Low *et al.*, 2019; Mignon-Ravix *et al.*, 2018; Muona *et al.*, 2016).
7 These findings suggest that DEE44 is caused by partial LoF of *UBA5*, and that *Uba5* knockout
8 models are not suitable to study disease pathogenesis. We generated a *Uba5*^{T2A-Gal4} allele that
9 corresponds to a severe LoF allele but also leads to expression of GAL4 in the same spatial and
10 temporal expression pattern of *Uba5*, which can then drive expression of the human *UBA5* cDNA
11 (Figure 1D). Expression of reference *UBA5* cDNA fully rescues the loss of *Uba5*, showing that the
12 proteins are functionally similar. This allowed us to assess the properties of the known *UBA5* variants
13 and establish an allelic series *in vivo*. We measured an array of phenotypes in flies that relate to the
14 phenotypes observed in affected individuals, including developmental delay, motor defects, and
15 bang sensitivity (seizure-like behavior). Based on the *in vivo* data we establish groups of variants
16 with different strengths from least severe to most severe: Groups IA, IB, II, and III (Table 1). To
17 facilitate the discussion, hereafter we also refer to the deletion, nonsense, frameshift, and splicing
18 variants observed in affected individuals as Group IV variants, although they were not functionally
19 tested in this study.

20 To correlate the allelic strength with the functional defects caused by the variants, we first examined
21 the stability of *UBA5* variants and assessed their activity in three key steps involved in *UBA5* enzyme
22 function: ATP binding, UFM1 activation, and UFM1 transthiolation. Two variants were not tested due
23 to instability during protein purification, while all remaining tested variants exhibited defects in at
24 least one assay, suggesting that they cause protein LoF (Table 2).

25 Group IA includes three variants, p.Asp389Gly, p.Asp389Tyr, and p.Ala371Thr. The three variants
26 fully rescued the defects caused by the loss of *Uba5* in flies, indicating that they do not affect *UBA5*
27 function or only cause a mild LoF of *UBA5*. The biochemical assays show that p.Asp389Gly and
28 p.Asp389Tyr only cause mild, but statistically insignificant defects in UFM1 activation, consistent
29 with the complete rescue of the loss of *Uba5* in humanized flies (Figure 3). The other variant,
30 p.Ala371Thr, has a minor allele frequency (MAF) of 0.0019 (517/274744 alleles) in general
31 population and is more frequent in Finnish population (MAF=0.0059, 149/24996 alleles) in gnomAD
32 v2.1.1. It is also the most commonly observed variant in affected individuals (Table S1). Individuals
33 homozygous for this variant have been identified in the Finnish and Icelandic population but they do
34 not present with obvious symptoms related to DEE44 (Arnadottir *et al.*, 2017; Colin *et al.*, 2016;
35 Muona *et al.*, 2016), consistent with our observations in flies. Interestingly, although the biochemical
36 assays showed no dramatic effect of Ala371Thr on *UBA5* stability, ATP binding, or UFM1 activation,
37 the transthiolation of UFM1 onto UFC1 is impaired. While it may seem intuitive that defective UFM1
38 activation or transthiolation would be equally detrimental, formation of the activated *UBA5*~UFM1
39 intermediate is the rate-limiting step of the reaction and hence more sensitive to perturbations (Gavin
40 *et al.*, 2014). Importantly, the defect is observed at 22 °C but not at 37 °C *in vitro*, indicating that
41 p.Ala371Thr is a very weak allele, consistent with all the *in vivo* and human genetics data.

42 Groups IB and II include variants that have an intermediate effect on the protein function *in vivo*.
43 They rescued the lethality of *Uba5* mutant flies, but cause phenotypes of various levels of severity
44 in adult flies. In biochemical assays, Group II variants exhibit a decreased capacity to bind ATP and
45 a mild loss in the ability to activate UFM1, though the limitations of our assay precluded statistically
46 significant effects among several variants. In Group IB, the p.Arg72Cys only causes a mild defect in
47 UFM1 activation, consistent with it being near but not directly involved in ATP binding. The novel
48 Group 1B variant reported herein, p.Gln312Leu, exhibited virtually no biochemical phenotype aside
49 from signs of local instability in the *UBA5* structure, which is stabilized in the presence of ATP. Among
50 the sites of Group IB and II variants, only the Val260 residue lies at the homodimeric interface while
51 no others lie immediately at a key interface for *UBA5* function. This is consistent with p.Val260Met

1 being the only variant among this set that exhibited severe activity defects *in vitro*. Despite this, all
2 Groups IB and II variants caused phenotypes in flies. It is possible that the subtle effects of these
3 substitutions are exacerbated in certain cellular conditions, such as ER stress.

4 Group III variants failed to rescue the lethality of the *Uba5* mutants, suggesting that they correspond
5 to severe LoF alleles. This group includes four variants, p.Arg55His, p.Gly168Glu, p.Leu254Pro,
6 and p.Cys303Arg. Two of the affected sites, Gly168 and Cys303, are buried in the UBA5 structure.
7 Interestingly, neither of these variants are soluble when produced in *E. coli*, indicating compromised
8 protein folding. The two remaining variants, p.Arg55His and p.Leu254Pro are in very close proximity
9 of the UBA5 active site (Figure 4B) and may affect ATP binding and cause decreased conformational
10 dynamics of the active site Cys. Both variants show a diminished capacity to bind ATP, and are
11 incapable of activating UFM1, consistent with the observations that they are very severe LoF alleles
12 in the fly. Hence, in Group III two alleles severely disrupt UBA5 protein stability while two others
13 affect enzyme catalysis.

14 Using our variant classification, we retrospectively analyzed the allelic combinations in reported
15 DEE44 cases. The most severely affected individual is homozygous for a Group II variant
16 p.Tyr53Phe. However, this individual was from a consanguineous family so other variants may
17 correspond to the phenotypic presentation of this individual (Cabrera-Serrano *et al.*, 2020). Most
18 (21/25) individuals are compound heterozygous for one allele from Group IA or IB and another allele
19 from Group III or IV (Table S1). This strongly suggests that the pairing of a mild LoF with a severe
20 LoF allele is required to allow individuals to survive and manifest the disease. However, two
21 individuals from a previous report (IA/II) and this study (IB/II) show that the disease is also
22 associated with a combination of two partial LoF alleles (Table S1). Finally, no affected individual is
23 free of alleles from Group II/III/IV, indicating that combinations of IA/IB alleles may not cause disease.
24 This is also supported by the observation that homozygous p.Ala371Thr (Group IA) individuals are
25 not affected (see above) (Arnadottir *et al.*, 2017; Colin *et al.*, 2016; Muona *et al.*, 2016). Our results
26 provide compelling evidence for the interpretation of existing and future variants as well as the
27 prediction of pathogenicity of allelic combinations in clinical genetic analyses, especially considering
28 the very limited number of reported individuals and the partial LoF mechanism of the disease.

29 Three other genes in the UFMylation pathway are associated with diseases that share symptoms
30 with DEE44. Variants in *UFSP2* (OMIM: #611482) cause another DEE (DEE106, OMIM: #620028)
31 (Ni *et al.*, 2021). *UFM1* (OMIM: #610553) is associated with hypomyelinating leukodystrophy 14
32 (HLD14, OMIM: #617899) (Hamilton *et al.*, 2017; Nahorski *et al.*, 2018). Variants in *UFC1* (OMIM:
33 #610554) cause a neurodevelopmental disorder with spasticity and poor growth (NEDSG, OMIM:
34 #618076) (Nahorski *et al.*, 2018). All these disorders cause global developmental delay, hypotonia,
35 spasticity, seizures, delayed myelination, and microcephaly, consistent with them sharing a similar
36 etiology. The UbiReal system developed herein can be easily adapted to test the variants in these
37 other UFMylation genes in future work. In addition, given that the genes are also highly conserved
38 in flies, the allelic strengths of the variants in these genes could also be established *in vivo* using
39 our fruit fly model.

41 **Material and Methods**

42 *Human genetics*

43 The proband was recruited through the Doernbecher Children's Hospital and informed consent was
44 obtained from legal guardians of the proband. The human study was approved by the Institutional
45 Review Board at Oregon Health & Science University. The legal guardians of the proband consent
46 to have the results of this research work published.

47 Trio exome sequencing was conducted by GeneDx using DNA extracted from blood. DNA was
48 enriched using a proprietary capture system developed by GeneDx for next-generation sequencing.
49 The enriched targets were simultaneously sequenced with paired-end reads on an Illumina platform.

1 Bi-directional sequence reads were assembled and aligned to Human Genome Sequencing Center
2 (HGSC) build 37, human reference genome 19. Reported variants were confirmed, if necessary, by
3 an appropriate orthogonal method.

5 *Drosophila strains and genetics*

6 All fruit fly strains used in this study were cultured using standard fly food in a 25°C incubator unless
7 a different culturing temperature was specifically indicated. The *Uba5*^{KO} mutant and the human *UAS-*
8 *UBA5* transgenic fly lines were generated in the Bellen lab (for methods, see below). The *Uba5*^{T2A-}
9 *Gal4* (#78928), *UAS-mCherry.nls* (#38424), *UAS-FLP* (#4540), *Uba5*^{GR} (#30359), *da-Gal4* (#5460),
10 *Act-Gal4* (#4414), *elav-Gal4* (#8765), and *repo-Gal4* (#7415) lines were obtained from the
11 Bloomington Drosophila Stock Center (BDSC).

13 *Generation of Uba5*^{KO} *allele*

14 The *Uba5*^{KO} allele was generated using CRISPR/Cas9 genome engineering technology as
15 previously described (Port *et al*, 2014). A TKO transgenic line expressing a *Uba5*-targeting single
16 guide RNA (sgRNA) is available from the BDSC (BDSC #81448) (Zirin *et al*, 2020). The sgRNA
17 (CAATCCGTACAGCCGCCTGA) targets the coding region in the Exon 1 of the only *Uba5* transcript.
18 To generate indel variants, the TKO flies were crossed to *nos-Cas9* transgenic flies (BDSC #78781)
19 and then the first generation (F1) female progenies carrying both sgRNA and Cas9 were crossed
20 with 1st chromosome balancer flies. Single F2 females were crossed with balancer flies again to
21 establish ~20 individual stocks with potential indel variants. Due to the lethality of *Uba5* mutants, the
22 stocks without unbalanced flies were screened for *Uba5* indel variant by genomic PCR and Sanger
23 sequencing. One mutant line with NM_132494.3 (*Uba5*):c.164_174del (p.Arg55ProfsTer87) variant
24 was isolated and designated as *Uba5*^{KO} allele in this study.

26 *Generation of UAS-UBA5 transgenic stocks*

27 Human *UAS-UBA5* transgenic fly lines were generated as previously described (Harnish *et al*, 2019).
28 In brief, the human *UBA5* cDNA sequences were cloned into the pGW-UAS-HA.attB vector (Bischof
29 *et al*, 2013) using the Gateway Cloning system (Thermo Fisher) and validated by sequencing. The
30 cDNA vectors were then injected into fly embryos and inserted into the VK37 (BDSC #24872)
31 docking site by φC31-mediated transgenesis (Venken *et al*, 2006). The human *UBA5* cDNA clone
32 corresponding to Genebank transcript NM_024818.6 was obtained from the Ultimate ORF Clones
33 library (Thermo Fisher). The *UBA5* variants were introduced into the reference cDNA using Q5 site-
34 directed mutagenesis (NEB) before the cDNA was cloned into the pGW-UAS-HA.attB vector.

36 *Immunostaining and confocal microscopy*

37 Larval and adult flies were dissected in 1X PBS and the specimens were processed for
38 immunostaining. Briefly, the tissues were fixed in 4% paraformaldehyde followed by normal goat
39 serum blocking and incubation in the primary antibody (Rat anti-Elav, Developmental Studies
40 Hybridoma Bank (DSHB) #7E8A10, 1:500; Mouse anti-Repo, DSHB #8D12, 1:50; Mouse anti-CSP,
41 DSHB #6D6, 1:200; FITC-conjugated anti-HRP, Jackson ImmunoResearch, 1:200). Cy5-conjugated
42 secondary antibodies were used to detect the primary antibodies. Samples were mounted on slides
43 using RapidClear (SUNJin Lab) and the images were captured using a confocal microscope (Zeiss
44 710). For NMJ morphology analysis, the NMJs from larval muscle 4 of abdominal segments 2, 3, or
45 4 were imaged and the bouton numbers and sizes were quantified using ImageJ software.

1 *Drosophila* lifespan assay

2 For the measurement of lifespan, freshly eclosed flies were collected in separate vials and
3 maintained at 25°C. Flies were transferred every day to fresh food in the first six days and every
4 other day afterward. Survival was determined during every transfer. The results are represented as
5 Kaplan-Meier curves.

7 *Drosophila* behavioral assay

8 To measure negative geotaxis, flies were transferred to a clean vial for at least 20 minutes prior to
9 the experiment. During the test, flies were tapped to the bottom of the vial and their negative geotaxis
10 climbing ability was measured. In each measurement, flies were allowed to climb for 30 seconds,
11 after which the climbing distances were measured (18 cm is maximum). To perform bang-sensitive
12 paralytic analyses, adult flies were transferred to a clean vial and vortexed at maximum speed for
13 10 seconds, after which the time required for flies to stand on their feet was counted (30 seconds is
14 maximum).

16 *Protein expression and purification*

17 The reference UBA5 gene and UFM1 cloned into pET15b and UFC1 cloned into pET32a were kind
18 gifts from R. Wiener (The Institute for Medical Research Israel-Canada). The UBA5 p.Met57Val and
19 p.Gln312Leu substitutions were cloned into this background by Quikchange PCR using Phusion
20 DNA polymerase. All other UBA5 variant substitutions were subcloned into pOPIN-B using the
21 constructs described above as templates. All of these constructs encoded N-terminal His-tags, and
22 were purified in a similar manner. After plasmid transformation into *E. coli* Rosetta (DE3) cells,
23 cultures were grown at 37 °C in Luria Broth containing 35 µg/mL chloramphenicol and 50 µg/mL of
24 kanamycin. Once an optical density (600 nm) between 0.4-0.6 was reached, cultures were cooled
25 to 18 °C and protein expression was induced with 0.5 mM IPTG. Cells were harvested by
26 centrifugation after 24 hours of expression and resuspended in 50 mM NaPO₄, 500 mM NaCl, 2 mM
27 β-mercaptoethanol, pH 8.0 (Buffer A). The cell pellet was then subjected to a freeze-thaw cycle
28 before adding DNase, PMSF, lysozyme and SigmaFAST Protease Inhibitor Cocktail (MiliporeSigma)
29 and allowed to incubate on ice for 30 min. The cell pellets were then lysed by either french press or
30 sonication, depending on the volume to be lysed. Lysates were then centrifuged at 35,000 xg, and
31 the clarified lysate was added to a column containing HisPur Cobalt affinity resin (ThermoFisher),
32 allowed to bind for 10 min, and washed with 1 L of Buffer A + 10 mM Imidazole. Proteins were then
33 eluted with 5 mL of Buffer A + 350 mM Imidazole in a stepwise manner for a total elution volume of
34 25 mL. Purity of the fractions were analyzed via SDS-PAGE and those with highest purity were
35 pooled and dialyzed overnight into 25 mM Tris, 100 mM NaCl, 2 mM DTT, pH 8.0 (Buffer B) at 4 °C.
36 After 24 hrs of dialysis, UBA5 proteins were further purified on a RESOURCE Q (Cytivia) anion
37 exchange chromatography column equilibrated in Buffer B. The protein was eluted over a 20 column
38 volume gradient against Buffer B + 1 M NaCl. Peak protein fractions were pooled and concentrated
39 using Amicon centrifugal filters (MiliporeSigma) before being applied to a HiLoad Superdex 75
40 16/600 pg size exclusion chromatography column (Cytivia) equilibrated in Buffer B. Following affinity
41 purification, the His-tags of UFM1 and UFC1 were removed by TEV cleavage during overnight
42 dialysis into Buffer B at 4 °C. Proteins were then concentrated using Amicon centrifugal filters and
43 applied to a HiLoad Superdex 75 16/600 pg as above. Peak fractions were evaluated for purity via
44 SDS-PAGE, pooled, and concentrated before being quantified by absorbance at 280 nm and flash
45 frozen above 10X their working stock concentration. All protein samples were stored at -80 °C.

47 *Fluorescence-based UBA5 activity assays*

48 UFM1-Alexa 488 substrates were prepared using an Alexa Fluor 488 TFP ester (ThermoFisher).

1 Labeling was performed at room temperature for 1 hr in 0.1 M sodium bicarbonate buffer at pH 7.5,
2 which directs labeling toward the N-terminus. Following labeling, excess fluorophore was quenched
3 with addition of 150 mM Tris pH 7.4 and separated by size exclusion chromatography on a HiLoad
4 Superdex 75 16/600 pg as above. Transfer and activation of UFM1 onto UBA5 and further
5 transthiolation to UFC1 was monitored by fluorescence polarization (FP) based on published
6 methods from the ubiquitin system (Franklin & Pruneda, 2019, 2023). FP was measured using a
7 BMG LabTech CLARIOstar plate reader at an excitation wavelength of 482 nm, an LP 504 nm
8 dichroic mirror, and an emission wavelength of 530 nm. Free UFM1 was used as a reference with a
9 target FP of 190. All assays were performed in black Greiner 384-well small-volume HiBase, low
10 protein-binding microplates. UFM1 and UBA5 stocks were prepared at 2X assay conditions in 25
11 mM NaPO₄, 150 mM NaCl, 10 mM MgCl₂, pH 7.4 (Buffer C). UFM1 was prepared at 100 nM in
12 Buffer C + 20 mM ATP (pH 7); UBA5 variants were prepared at 1 μM in Buffer C. UFC1 was prepared
13 at 3 μM (10X assay concentration) in Buffer C. Final assay conditions in 20 μL volumes were 50 nM
14 UFM1, 500 nM UBA5 variants, and 300 nM UFC1 in Buffer C + 10 mM ATP. FP data was first
15 collected for the substrate only to establish a baseline before addition of UBA5 variants at 1:1 ratio
16 to reach the described assay conditions. FP values were collected in 45-second intervals until the
17 reference UBA5 readings plateaued, at which point UFC1 was added at 1:10 ratio to achieve final
18 assay conditions. Reactions were performed in triplicate for each of three experimental replicates,
19 both at 22 °C and 37 °C. AUC calculations were performed using Prism 9.5, with baseline values
20 calculated from data collected prior to addition of UBA5/UFC1. For the UFM1 activation stage, AUC
21 was determined over a 45-minute window following addition of UBA5. For the UFM1 transthiolation
22 stage, AUC was determined over a 20-minute window following addition of UFC1.

24 *Gel-based UBA5 activation and transthiolation assay*

25 Conditions for the gel-based assay were identical to those described above for the 22 °C FP assays.
26 Parallel reactions were prepared, one to be read out by FP using the CLARIOstar plate reader and
27 the other was left in a low light environment at room temperature. After 15 minutes of establishing a
28 baseline FP reading for UFM1 alone, a 20 μL sample was taken from the parallel reaction and
29 quenched using non-reducing sample buffer. FP readings were paused and reference UBA5 was
30 added to both reactions before continuing FP data collection. The FP values were allowed to plateau
31 before another 20 μL sample was collected from the parallel reaction and quenched with non-
32 reducing sample buffer. FP readings were then paused and UFC1 was added to both reactions
33 before continuing FP data collection. The FP values were allowed to plateau before taking a final 20
34 μL sample from the parallel reaction and quenching with non-reducing sample buffer. Gel samples
35 were run on a TGX 4-20% SDS-PAGE gradient gel (Bio-Rad). The resulting gel was imaged using
36 a Sapphire Biomolecular Imager (Azure Biosystems). This experiment was performed in triplicate.

38 *Thermal shift assay*

39 The thermal shift assay was conducted in MicroAmp Fast 96-Well Reaction Plates (Applied
40 Biosystems) with SYPRO Orange Protein Gel Stain (MiliporeSigma) using a QuantStudio 3 Real-
41 Time PCR system (Applied Biosystems). Assays were performed in 20 μL volumes containing 5 μM
42 UBA5 variants and 20X SYPRO dye (diluted from a 5000X stock) in 25 mM NaPO₄, 150 mM NaCl,
43 10 mM MgCl₂, pH 7.4 with or without 5 mM ATP. The protocol ramped temperature from 22 °C to 99
44 °C over a gradient of 0.1 °C every 5 seconds, and fluorescence was monitored using an excitation
45 wavelength of 580 ± 10 nm and an emission wavelength of 623 ± 14 nm.

47 *Statistical analysis*

48 Statistical analyses were carried out using the Student's unpaired two-tailed t test for comparison of
49 two groups or the Welch's t test for data normalized to reference UBA5. Multiple comparisons within

1 the group were tested against the corresponding control. Kaplan-Meier survival curves were
2 analyzed using Gehan-Breslow-Wilcoxon test and log-rank test. Calculated p values of less than
3 0.05 were considered significant. All statistical analyses were performed using GraphPad Prism,
4 version 9.5.0 (GraphPad Software).

5
6

1 **Acknowledgements**

2 We thank the proband and his family for agreeing to participate in this study. We thank the Bellen
3 and Yamamoto lab members for their discussion and suggestions in this study. We thank Ms.
4 Hongling Pan for the injection of transgenic fly lines. We thank the BDSC for fly stocks, the DSHB
5 for antibodies, and R. Wiener (The Institute for Medical Research Israel-Canada) for sharing
6 plasmids.

7 H.J.B., O.K. and S.Y. were supported by the Office of Research Infrastructure Programs (ORIP) of
8 the NIH (award U54 OD030165). H.J.B. was also supported by the ORIP of the NIH (awards R24
9 OD022005 and R24 OD031447), the Huffington Foundation, and the Jan & Dan Duncan
10 Neurological Research Institute at Texas Children's Hospital. The work was also supported by the
11 Baylor College of Medicine IDDRC P50HD103555 from the Eunice Kennedy Shriver National
12 Institute of Child Health and Human Development for use of the Microscopy Core facilities. J.N.P.
13 and R.J.N. were supported by the OHSU Molecular Microbiology and Immunology Interdisciplinary
14 Pilot Award and the Oregon Clinical and Translational Research Institute's Biomedical Innovation
15 Program NCATS UL1TR002369 from the NIH. J.N.P. was also supported by an NIGMS R35 grant
16 (R35 GM142486), and R.J.N. was also supported by a VA CDA2 grant (5IK2BX004523). D.A.S. and
17 L.C.B. were supported by the NIH common fund through the Office of Strategic Coordination/Office
18 of the NIH Direction (award U01 HG007690), the Hill Family Fund for the Diagnosis, Management
19 of Rare and Undiagnosed Diseases at Mass General, and American Institute for Neuro Integrative
20 Development Inc (AIND).

21 **Declaration of interests**

22 The authors declare no competing interests.

23 **Web resources**

24 OMIM, <https://omim.org/>

25 DIOPT, https://www.flyrnai.org/cgi-bin/DRSC_orthologs.pl/

26 gnomAD, <https://gnomad.broadinstitute.org/>

27 CADD, <https://cadd.gs.washington.edu/>

28 SIFT, <https://sift.bii.a-star.edu.sg/>

29 PolyPhen2, <http://genetics.bwh.harvard.edu/pph2/>

30 MutationTaster, <https://www.mutationtaster.org/>

31 PROVEAN, <http://provean.jcvi.org/>

References

- 1
2 Arnadottir GA, Jensson BO, Marelsson SE, Sulem G, Oddsson A, Kristjansson RP, Benonisdottir S,
3 Gudjonsson SA, Masson G, Thorisson GA *et al* (2017) Compound heterozygous mutations in UBA5
4 causing early-onset epileptic encephalopathy in two sisters. *BMC Med Genet* 18: 103
5 Bacik JP, Walker JR, Ali M, Schimmer AD, Dhe-Paganon S (2010) Crystal structure of the human
6 ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1
7 enzyme. *J Biol Chem* 285: 20273-20280
8 Bellen HJ, Yamamoto S (2015) Morgan's legacy: fruit flies and the functional annotation of
9 conserved genes. *Cell* 163: 12-14
10 Bischof J, Bjorklund M, Furger E, Schertel C, Taipale J, Basler K (2013) A versatile platform for
11 creating a comprehensive UAS-ORFeome library in Drosophila. *Development* 140: 2434-2442
12 Briere LC, Walker MA, High FA, Cooper C, Rogers CA, Callahan CJ, Ishimura R, Ichimura Y, Caruso
13 PA, Sharma N *et al* (2021) A description of novel variants and review of phenotypic spectrum in
14 UBA5-related early epileptic encephalopathy. *Cold Spring Harb Mol Case Stud* 7
15 Cabrera-Serrano M, Coote DJ, Azmanov D, Goullee H, Andersen E, McLean C, Davis M, Ishimura
16 R, Stark Z, Vallat JM *et al* (2020) A homozygous UBA5 pathogenic variant causes a fatal congenital
17 neuropathy. *J Med Genet* 57: 835-842
18 Cappadocia L, Lima CD (2018) Ubiquitin-like Protein Conjugation: Structures, Chemistry, and
19 Mechanism. *Chem Rev* 118: 889-918
20 Colin E, Daniel J, Ziegler A, Wakim J, Scrivo A, Haack TB, Khiati S, Denomme AS, Amati-Bonneau
21 P, Charif M *et al* (2016) Biallelic Variants in UBA5 Reveal that Disruption of the UFM1 Cascade Can
22 Result in Early-Onset Encephalopathy. *Am J Hum Genet* 99: 695-703
23 Daida A, Hamano SI, Ikemoto S, Matsuura R, Nakashima M, Matsumoto N, Kato M (2018) Biallelic
24 loss-of-function UBA5 mutations in a patient with intractable West syndrome and profound failure to
25 thrive. *Epileptic Disord* 20: 313-318
26 Davie K, Janssens J, Koldere D, De Waegeneer M, Pech U, Kreft L, Aibar S, Makhzami S,
27 Christiaens V, Bravo Gonzalez-Blas C *et al* (2018) A Single-Cell Transcriptome Atlas of the Aging
28 Drosophila Brain. *Cell* 174: 982-998 e920
29 Diao F, Ironfield H, Luan H, Diao F, Shropshire WC, Ewer J, Marr E, Potter CJ, Landgraf M, White
30 BH (2015) Plug-and-play genetic access to drosophila cell types using exchangeable exon
31 cassettes. *Cell Rep* 10: 1410-1421
32 Duan R, Shi Y, Yu L, Zhang G, Li J, Lin Y, Guo J, Wang J, Shen L, Jiang H *et al* (2016) UBA5
33 Mutations Cause a New Form of Autosomal Recessive Cerebellar Ataxia. *PLoS One* 11: e0149039
34 Franklin TG, Pruneda JN (2019) A High-Throughput Assay for Monitoring Ubiquitination in Real Time.
35 *Front Chem* 7: 816
36 Franklin TG, Pruneda JN (2023) Observing Real-Time Ubiquitination in High Throughput with
37 Fluorescence Polarization. *Methods Mol Biol* 2581: 3-12
38 Gavin JM, Hoar K, Xu Q, Ma J, Lin Y, Chen J, Chen W, Bruzzese FJ, Harrison S, Mallender WD *et*
39 *al* (2014) Mechanistic study of Uba5 enzyme and the Ufm1 conjugation pathway. *J Biol Chem* 289:
40 22648-22658
41 Goodman LD, Cope H, Nil Z, Ravenscroft TA, Charng WL, Lu S, Tien AC, Pfundt R, Koolen DA,
42 Haaxma CA *et al* (2021) TNPO2 variants associate with human developmental delays, neurologic
43 deficits, and dysmorphic features and alter TNPO2 activity in Drosophila. *Am J Hum Genet* 108:
44 1669-1691
45 Habisov S, Huber J, Ichimura Y, Akutsu M, Rogova N, Loehr F, McEwan DG, Johansen T, Dikic I,
46 Doetsch V *et al* (2016) Structural and Functional Analysis of a Novel Interaction Motif within UFM1-

1 activating Enzyme 5 (UBA5) Required for Binding to Ubiquitin-like Proteins and Ufm1ylation. *J Biol*
2 *Chem* 291: 9025-9041

3 Hamilton EMC, Bertini E, Kalaydjieva L, Morar B, Dojcakova D, Liu J, Vanderver A, Curiel J, Persoon
4 CM, Diodato D *et al* (2017) UFM1 founder mutation in the Roma population causes recessive variant
5 of H-ABC. *Neurology* 89: 1821-1828

6 Harnish JM, Deal SL, Chao HT, Wangler MF, Yamamoto S (2019) In Vivo Functional Study of
7 Disease-associated Rare Human Variants Using *Drosophila*. *J Vis Exp*

8 Hu Y, Comjean A, Rodiger J, Liu Y, Gao Y, Chung V, Zirin J, Perrimon N, Mohr SE (2021)
9 FlyRNAi.org-the database of the *Drosophila* RNAi screening center and transgenic RNAi project:
10 2021 update. *Nucleic Acids Res* 49: D908-D915

11 Kang SH, Kim GR, Seong M, Baek SH, Seol JH, Bang OS, Ovaa H, Tatsumi K, Komatsu M, Tanaka
12 K *et al* (2007) Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. *J*
13 *Biol Chem* 282: 5256-5262

14 Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, Ueno T, Kominami E, Natsume T,
15 Tanaka K (2004) A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. *EMBO J* 23:
16 1977-1986

17 Kumar M, Padala P, Fahoum J, Hassouna F, Tsaban T, Zoltsman G, Banerjee S, Cohen-Kfir E,
18 Dessau M, Rosenzweig R *et al* (2021) Structural basis for UFM1 transfer from UBA5 to UFC1. *Nat*
19 *Commun* 12: 5708

20 Leader DP, Krause SA, Pandit A, Davies SA, Dow JAT (2018) FlyAtlas 2: a new version of the
21 *Drosophila melanogaster* expression atlas with RNA-Seq, miRNA-Seq and sex-specific data.
22 *Nucleic Acids Res* 46: D809-D815

23 Lee PT, Zirin J, Kanca O, Lin WW, Schulze KL, Li-Kroeger D, Tao R, Devereaux C, Hu Y, Chung V
24 *et al* (2018) A gene-specific T2A-GAL4 library for *Drosophila*. *Elife* 7

25 Li H, Janssens J, De Waegeneer M, Kolluru SS, Davie K, Gardeux V, Saelens W, David FPA, Brbic
26 M, Spanier K *et al* (2022) Fly Cell Atlas: A single-nucleus transcriptomic atlas of the adult fruit fly.
27 *Science* 375: eabk2432

28 Liang JR, Lingeman E, Luong T, Ahmed S, Muhar M, Nguyen T, Olzmann JA, Corn JE (2020) A
29 Genome-wide ER-phagy Screen Highlights Key Roles of Mitochondrial Metabolism and ER-
30 Resident UFMylation. *Cell* 180: 1160-1177 e1120

31 Liu J, Guan D, Dong M, Yang J, Wei H, Liang Q, Song L, Xu L, Bai J, Liu C *et al* (2020) UFMylation
32 maintains tumour suppressor p53 stability by antagonizing its ubiquitination. *Nat Cell Biol* 22: 1056-
33 1063

34 Low KJ, Baptista J, Babiker M, Caswell R, King C, Ellard S, Scurr I (2019) Hemizygous UBA5
35 missense mutation unmasking recessive disorder in a patient with infantile-onset encephalopathy,
36 acquired microcephaly, small cerebellum, movement disorder and severe neurodevelopmental
37 delay. *Eur J Med Genet* 62: 97-102

38 Lu S, Hernan R, Marcogliese PC, Huang Y, Gertler TS, Akcaboy M, Liu S, Chung HL, Pan X, Sun X
39 *et al* (2022a) Loss-of-function variants in TIAM1 are associated with developmental delay,
40 intellectual disability, and seizures. *Am J Hum Genet* 109: 571-586

41 Lu S, Ma M, Mao X, Bacino CA, Jankovic J, Sutton VR, Bartley JA, Wang X, Rosenfeld JA, Beleza-
42 Meireles A *et al* (2022b) De novo variants in FRMD5 are associated with developmental delay,
43 intellectual disability, ataxia, and abnormalities of eye movement. *Am J Hum Genet* 109: 1932-1943

44 Ma M, Zhang X, Zheng Y, Lu S, Pan X, Mao X, Pan H, Chung HL, Wang H, Guo H *et al* (2023) The
45 fly homolog of SUPT16H, a gene associated with neurodevelopmental disorders, is required in a
46 cell-autonomous fashion for cell survival. *Hum Mol Genet* 32: 984-997

- 1 Mashahreh B, Hassouna F, Soudah N, Cohen-Kfir E, Strulovich R, Haitin Y, Wiener R (2018) Trans-
2 binding of UFM1 to UBA5 stimulates UBA5 homodimerization and ATP binding. *FASEB J* 32: 2794-
3 2802
- 4 Mignon-Ravix C, Milh M, Kaiser CS, Daniel J, Riccardi F, Cacciagli P, Nagara M, Busa T, Liebau E,
5 Villard L (2018) Abnormal function of the UBA5 protein in a case of early developmental and epileptic
6 encephalopathy with suppression-burst. *Hum Mutat* 39: 934-938
- 7 Millrine D, Cummings T, Matthews SP, Peter JJ, Magnussen HM, Lange SM, Macartney T,
8 Lamoliatte F, Knebel A, Kulathu Y (2022) Human UFSP1 is an active protease that regulates UFM1
9 maturation and UFMylation. *Cell Rep* 40: 111168
- 10 Millrine D, Peter JJ, Kulathu Y (2023) A guide to UFMylation, an emerging posttranslational
11 modification. *FEBS J*
- 12 Muona M, Ishimura R, Laari A, Ichimura Y, Linnankivi T, Keski-Filppula R, Herva R, Rantala H,
13 Paetau A, Poyhonen M *et al* (2016) Biallelic Variants in UBA5 Link Dysfunctional UFM1 Ubiquitin-
14 like Modifier Pathway to Severe Infantile-Onset Encephalopathy. *Am J Hum Genet* 99: 683-694
- 15 Nagarkar-Jaiswal S, Lee PT, Campbell ME, Chen K, Anguiano-Zarate S, Gutierrez MC, Busby T, Lin
16 WW, He Y, Schulze KL *et al* (2015) A library of MiMICs allows tagging of genes and reversible,
17 spatial and temporal knockdown of proteins in *Drosophila*. *Elife* 4
- 18 Nahorski MS, Maddirevula S, Ishimura R, Alsahli S, Brady AF, Begemann A, Mizushima T, Guzman-
19 Vega FJ, Obata M, Ichimura Y *et al* (2018) Biallelic UFM1 and UFC1 mutations expand the essential
20 role of ufmylation in brain development. *Brain* 141: 1934-1945
- 21 Ni M, Afroze B, Xing C, Pan C, Shao Y, Cai L, Cantarel BL, Pei J, Grishin NV, Hewson S *et al* (2021)
22 A pathogenic UFSP2 variant in an autosomal recessive form of pediatric neurodevelopmental
23 anomalies and epilepsy. *Genet Med* 23: 900-908
- 24 Oweis W, Padala P, Hassouna F, Cohen-Kfir E, Gibbs DR, Todd EA, Berndsen CE, Wiener R (2016)
25 Trans-Binding Mechanism of Ubiquitin-like Protein Activation Revealed by a UBA5-UFM1 Complex.
26 *Cell Rep* 16: 3113-3120
- 27 Padala P, Oweis W, Mashahreh B, Soudah N, Cohen-Kfir E, Todd EA, Berndsen CE, Wiener R
28 (2017) Novel insights into the interaction of UBA5 with UFM1 via a UFM1-interacting sequence. *Sci*
29 *Rep* 7: 508
- 30 Peter JJ, Magnussen HM, DaRosa PA, Millrine D, Matthews SP, Lamoliatte F, Sundaramoorthy R,
31 Kopito RR, Kulathu Y (2022) A non-canonical scaffold-type E3 ligase complex mediates protein
32 UFMylation. *EMBO J* 41: e111015
- 33 Port F, Chen HM, Lee T, Bullock SL (2014) Optimized CRISPR/Cas tools for efficient germline and
34 somatic genome engineering in *Drosophila*. *Proc Natl Acad Sci U S A* 111: E2967-2976
- 35 Qin B, Yu J, Nowsheen S, Wang M, Tu X, Liu T, Li H, Wang L, Lou Z (2019) UFL1 promotes histone
36 H4 ufmylation and ATM activation. *Nat Commun* 10: 1242
- 37 Ravenscroft TA, Janssens J, Lee PT, Tepe B, Marcogliese PC, Makhzami S, Holmes TC, Aerts S,
38 Bellen HJ (2020) *Drosophila* Voltage-Gated Sodium Channels Are Only Expressed in Active
39 Neurons and Are Localized to Distal Axonal Initial Segment-like Domains. *J Neurosci* 40: 7999-8024
- 40 Scavone F, Gumbin SC, Da Rosa PA, Kopito RR (2023) RPL26/uL24 UFMylation is essential for
41 ribosome-associated quality control at the endoplasmic reticulum. *Proc Natl Acad Sci U S A* 120:
42 e2220340120
- 43 Song J, Tanouye MA (2008) From bench to drug: human seizure modeling using *Drosophila*. *Prog*
44 *Neurobiol* 84: 182-191
- 45 Soudah N, Padala P, Hassouna F, Kumar M, Mashahreh B, Lebedev AA, Isupov MN, Cohen-Kfir E,
46 Wiener R (2019) An N-Terminal Extension to UBA5 Adenylation Domain Boosts UFM1 Activation:

1 Isoform-Specific Differences in Ubiquitin-like Protein Activation. *J Mol Biol* 431: 463-478
2 Tatsumi K, Sou YS, Tada N, Nakamura E, Iemura S, Natsume T, Kang SH, Chung CH, Kasahara M,
3 Kominami E *et al* (2010) A novel type of E3 ligase for the Ufm1 conjugation system. *J Biol Chem*
4 285: 5417-5427
5 Tatsumi K, Yamamoto-Mukai H, Shimizu R, Waguri S, Sou YS, Sakamoto A, Taya C, Shitara H, Hara
6 T, Chung CH *et al* (2011) The Ufm1-activating enzyme Uba5 is indispensable for erythroid
7 differentiation in mice. *Nat Commun* 2: 181
8 Tepe B, Macke EL, Niceta M, Weisz Hubshman M, Kanca O, Schultz-Rogers L, Zarate YA, Schaefer
9 GB, Granadillo De Luque JL, Wegner DJ *et al* (2023) Bi-allelic variants in INTS11 are associated
10 with a complex neurological disorder. *Am J Hum Genet*
11 van der Veen AG, Ploegh HL (2012) Ubiquitin-like proteins. *Annu Rev Biochem* 81: 323-357
12 Venken KJ, He Y, Hoskins RA, Bellen HJ (2006) P[acman]: a BAC transgenic platform for targeted
13 insertion of large DNA fragments in *D. melanogaster*. *Science* 314: 1747-1751
14 Venken KJ, Popodi E, Holtzman SL, Schulze KL, Park S, Carlson JW, Hoskins RA, Bellen HJ,
15 Kaufman TC (2010) A molecularly defined duplication set for the X chromosome of *Drosophila*
16 *melanogaster*. *Genetics* 186: 1111-1125
17 Walczak CP, Leto DE, Zhang L, Riepe C, Muller RY, DaRosa PA, Ingolia NT, Elias JE, Kopito RR
18 (2019) Ribosomal protein RPL26 is the principal target of UFMylation. *Proc Natl Acad Sci U S A* 116:
19 1299-1308
20 Wang L, Xu Y, Rogers H, Saidi L, Noguchi CT, Li H, Yewdell JW, Guydosh NR, Ye Y (2020)
21 UFMylation of RPL26 links translocation-associated quality control to endoplasmic reticulum protein
22 homeostasis. *Cell Res* 30: 5-20
23 Wang Z, Gong Y, Peng B, Shi R, Fan D, Zhao H, Zhu M, Zhang H, Lou Z, Zhou J *et al* (2019) MRE11
24 UFMylation promotes ATM activation. *Nucleic Acids Res* 47: 4124-4135
25 Wesch N, Lohr F, Rogova N, Dotsch V, Rogov VV (2021) A Concerted Action of UBA5 C-Terminal
26 Unstructured Regions Is Important for Transfer of Activated UFM1 to UFC1. *Int J Mol Sci* 22
27 Xie S (2014) Characterization, crystallization and preliminary X-ray crystallographic analysis of the
28 human Uba5 C-terminus-Ufc1 complex. *Acta Crystallogr F Struct Biol Commun* 70: 1093-1097
29 Yoo HM, Kang SH, Kim JY, Lee JE, Seong MW, Lee SW, Ka SH, Sou YS, Komatsu M, Tanaka K *et*
30 *al* (2014) Modification of ASC1 by UFM1 is crucial for ERalpha transactivation and breast cancer
31 development. *Mol Cell* 56: 261-274
32 Zhu H, Bhatt B, Sivaprakasam S, Cai Y, Liu S, Kodeboyina SK, Patel N, Savage NM, Sharma A,
33 Kaufman RJ *et al* (2019) Ufbp1 promotes plasma cell development and ER expansion by modulating
34 distinct branches of UPR. *Nat Commun* 10: 1084
35 Zirin J, Hu Y, Liu L, Yang-Zhou D, Colbeth R, Yan D, Ewen-Campen B, Tao R, Vogt E, VanNest S *et*
36 *al* (2020) Large-Scale Transgenic *Drosophila* Resource Collections for Loss- and Gain-of-Function
37 Studies. *Genetics* 214: 755-767
38

Figure Legends

Figure 1. UFMylation pathway, conservation of UBA5, and generation of fly *Uba5* LoF alleles

(A) A diagram showing the UFMylation pathway. Details of the biochemical processes in the pathway are described in the main text. In UBA5 proteins, only the adenylation domains are shown in the diagram.

(B) A diagram of the UBA5:UFM1:UFC1 complex. In the complex, two copies of UBA5 form a homodimer that interacts with UFM1 via a trans-binding mechanism. The activation of UFM1 requires the adenylation domain of one UBA5 subunit and the UFM1-interacting sequence (UIS) of the other UBA5 subunit in the complex. The opposing protomer of the UBA5 homodimer also contributes a UFC1-binding sequence (UBS) that is required for UFM1 transthiolation.

(C) Alignment of the human UBA5 and fly *Uba5* protein sequences. The functional domains of UBA5 are marked in colored boxes. The DEE44-associated variants are marked in the protein topology diagram and the protein sequence alignment (letters in red).

(D) Generation of the *Uba5*^{T2A-Gal4} allele and the uses of the allele in flippase (FLP)-mediated conversion. The expression of the GAL4 to drive a fluorescent protein allows assessment of gene expression, and humanization of the flies by expression of human *UBA5* cDNA.

(E) Generation of *Uba5* null allele by CRISPR-mediated indel formation.

(F) Loss of *Uba5* causes lethality in early developmental stage. The lethality is rescued by a genomic rescue construct, the expression of FLP (*Uba5*^{T2A-Gal4} mutants only), and the expression of human *UBA5* cDNA.

Figure 2. *Uba5* is expressed in a subset of neurons and glial cells in fly CNS

(A) The expression of nuclear localized mCherry (mCherry.nls) driven by the *Uba5*^{T2A-Gal4} allele (*Uba5*^{T2A-Gal4} > *mCherry.nls*) shows that *Uba5* is expressed in L3 larvae and adult flies.

(B and C) The larval CNS and adult brain of *Uba5*^{T2A-Gal4} > *mCherry.nls* animals were immunostained with a neuronal (Elav, Panel B) or glial marker (Repo, Panel C). Maximum projections of confocal z-stack images are shown. Single plane, high magnification images of the regions indicated by the dashed squares are shown on the right to visualize the colocalizations between mCherry and the immunostaining signals. Arrows indicate cells that colocalize both markers. Scale bar, 100 μ m.

Figure 3. DEE44-associated variants exhibit different rescuing abilities in flies

(A) The DEE44-associated *UBA5* variants rescued the lethality of *Uba5* mutant flies with varying efficiency. *Uba5*^{T2A-Gal4}/FM7 females were crossed with *UAS-UBA5* males and the viability of *Uba5*^{T2A-Gal4}/Y; *UAS-UBA5*/+ progenies were measured by Mendelian ratio and indicated by color codes: red, zero viability; yellow, partial viability (< 90% of expected number); green, full viability (90% and above).

(B) Three variants caused developmental delay in *Uba5*^{T2A-Gal4}/Y; *UAS-UBA5*/+ flies. The embryos were collected within 6 hours and the number of eclosed adult flies was counted at the same time every day. Three replicates were performed in each group.

(C) Five variants caused reduced lifespan in *Uba5*^{T2A-Gal4}/Y; *UAS-UBA5*/+ flies.

(D) Five variants caused progressive climbing defects in *Uba5*^{T2A-Gal4}/Y; *UAS-UBA5*/+ flies. Flies were tested on Day 7 and Day 30. The climbing activity of *CantonS* wildtype flies is shown as reference. Numbers of animals (n values) in each group are indicated under the bars.

(E) Three variants caused a bang-sensitive phenotype in *Uba5^{T2A-Gal4/Y}; UAS-UBA5/+* flies. Flies were tested on Day 30. The bang-sensitivity of *CantonS* wildtype flies is shown as reference. Numbers of animals (n values) in each group are indicated under the bars.

(B-E) Flies were cultured under 25 °C. The results of DEE4 variant-expressing flies are compared with the result of reference *UBA5*-expressing flies. Results are presented as means ± SEM. Statistical analyses were performed via two-sided, unpaired Student's t-test. ns, not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

Figure 4. Structural analysis of UBA5 variants

(A) Composite model of a UBA5 homodimer (green and blue) bound to ATP (grey sticks), UFM1 (magenta), and UFC1 (gold). The model was built using a series of UBA5 complex structures with UFM1 and UFC1 (PDB 6H77, 7NW1, and a modelled UBA5:UFC1 complex(Kumar *et al.*, 2021; Soudah *et al.*, 2019). Functional residues comprising the active site cysteines of UBA5 and UFC1, as well as the C-terminus of UFM1 are shown in yellow spheres. UBA5 variants are shown in red spheres and are labeled with their predicted structural effects.

(B) Close-up view of variants (red sticks) within the UBA5 active site (yellow sphere), ATP binding pocket, and homodimerization interface.

(C) Close-up view of variants (red sticks) expected to impact UBA5 protein stability (results shown in the following figures).

Figure 5. Preparation and stability of UBA5 variant proteins

(A) Coomassie-stained SDS-PAGE analysis of all purified UBA5 variant proteins.

(B) Thermal shift assay measuring the melting temperature (T_m) of all UBA5 variant proteins, with the exception of p.Gly168Glu and p.Cys303Arg which could not be produced. The p.Gln312Leu variant displayed two melting curves. Experiments were performed in triplicate over three biological replicates.

(C) Change in melting temperature for all UBA5 variants in the presence of 5 mM ATP. Upon ATP addition, the p.Gln312Leu variant transitioned to a single melting curve. Experiments were performed in triplicate over three biological replicates.

(B-C) Statistical analyses were performed via unpaired Student's t-test. ns, not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

Figure 6. Measuring UFM1 activation and transthiolation with UbiReal

(A) Cartoon schematic illustrating the complexes formed during UFM1 activation and transthiolation, as well as their expected molecular weights. The fluorescent group attached to UFM1 is denoted by an orange star. The expected molecular weight for the UBA5~UFM1 intermediate is based on a UBA5 homodimer with one UFM1 molecule.

(B) Proof-of-concept UbiReal assay monitoring the fluorescence polarization (FP) of Alexa488-labeled UFM1 alone (species 1), following addition of UBA5 (species 2), and following addition of UFC1 (species 3).

(C) Fluorescence scan of samples described in (B) separated by SDS-PAGE, illustrating the formation of activated UFM1 complexes. Each species is labeled with the analogous cartoon schematic presented in (A).

(D) UbiReal assay tracking UFM1 activation by reference and variant UBA5 proteins over time.

1 (E) Area Under the Curve quantification of UFM1 activation performed at 22 °C. Experiments were
2 performed in triplicate over three biological replicates. Statistical analyses were performed using a
3 Welch's t test with comparison to the reference UBA5 data.

4 (F) As in (E), for reactions performed at 37 °C.

5 (G) UbiReal assay tracking UFM1 transthiolation for reference UBA5 and variants that showed little
6 or no effect on activation.

7 (H) Area Under the Curve quantification of UFM1 transthiolation performed at 22 °C. Experiments
8 were performed in triplicate over three biological replicates. Statistical analyses were performed
9 using a Welch's t test with comparison to the reference UBA5 data.

10 (I) As in (H), for reactions performed at 37 °C.

11 (E-F, H-I) Statistical analyses were performed via Welch's t-test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$;
12 **** $p < 0.0001$.

1 **Table 1. Summary of phenotypes of humanized flies expressing UBA5 variants**

	Variants	Survival rate	Dev. delay	Lifespan	Climbing defects	Bang sensitivity
Group IA	p.Ala371Thr	Normal	No	Normal	No	No
	p.Asp389Gly	Normal	No	Normal	No	No
	p.Asp389Tyr	Normal	No	Normal	No	No
Group IB	p.Arg72Cys	Normal	No	Decreased	Yes	No
	p.Gln312Leu	Normal	No	Decreased	Yes	No
Group II	p.Tyr53Phe	Decreased	Yes	Decreased	Yes	Yes
	p.Met57Val	Decreased	Yes	Decreased	Yes	Yes
	p.Val260Met	Decreased	Yes	Decreased	Yes	Yes
Group III	p.Arg55His	Lethal	N.A.	N.A.	N.A.	N.A.
	p.Gly168Glu	Lethal	N.A.	N.A.	N.A.	N.A.
	p.Leu254Pro	Lethal	N.A.	N.A.	N.A.	N.A.
	p.Cys303Arg	Lethal	N.A.	N.A.	N.A.	N.A.

2

3 **Table 2. Summary of protein stability and functions of UBA5 variants**


	Variants	Thermal stability	ATP binding defect***	UFM1 activation	UFM1 transthiolation
Group IA	p.Ala371Thr	Decreased	No defect	Normal	Decreased
	p.Asp389Gly	Normal	No defect	Decreased	Decreased
	p.Asp389Tyr	Normal	No defect	Decreased	Normal
Group IB	p.Arg72Cys	Decreased	No defect	Decreased	Normal
	p.Gln312Leu	Local destabilization*	No defect	Normal	Normal
Group II	p.Tyr53Phe	Normal	Strong	Decreased	N.A.
	p.Met57Val	Normal	Intermediate	Normal	Normal
	p.Val260Met	Decreased	Intermediate	Decreased	N.A.
Group III	p.Arg55His	Normal	Strong	Near baseline	N.A.
	p.Gly168Glu	N.A.**	N.A.	N.A.	N.A.
	p.Leu254Pro	Decreased	Strong	Near baseline	N.A.
	p.Cys303Arg	N.A.**	N.A.	N.A.	N.A.

4 * See Results and Figure 5B

5 ** Insoluble in protein purification


6 *** Strong, 4-5 °C in T_m shift; intermediate, 6-8 °C in T_m shift. Reference UBA5 shows 13 °C in T_m shift upon ATP addition.

7

A*Uba5^{T2A-Gal4}>mCherry.nls*


L3 larva

Adult fly

B*Uba5^{T2A-Gal4}>mCherry.nls* anti-Elav (Neuron) Merge Single plane

Larval CNS

Adult brain

C*Uba5^{T2A-Gal4}>mCherry.nls* anti-Repo (Glia) Merge Single plane


Larval CNS

Adult brain


A

<i>Uba5^{T2A-Gal4} / Y; UAS-UBA5 / +</i>	Viability @ 29°C	Viability @ 25°C	Viability @ 18°C
Reference	93.7%	95.7%	108%
<i>p.C250A</i> (Enzyme dead)	0%	0%	0%
<i>p.Y53F</i>	88.3%	84.8%	75%
<i>p.R55H</i>	0%	0%	0%
<i>p.M57V</i>	74.5%	73.5%	52.7%
<i>p.R72C</i>	92.0%	91.7%	93.4%
<i>p.G168E</i>	0%	0%	0%
<i>p.L254P</i>	0%	0%	0%
<i>p.V260M</i>	92.0%	94.9%	46.2%
<i>p.C303R</i>	0%	0%	0%
<i>p.Q312L</i>	93.0%	103.5%	94.8%
<i>p.A371T</i>	97.0%	107.9%	107.3%
<i>p.D389G</i>	100.9%	101.9%	94.3%
<i>p.D389Y</i>	92.8%	94.5%	96.1%


B




C




D




E



A



B



C

